Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (epicardial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: sgn-30, iratumumab, brentuximab vedotin +1 | 0.81 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7052
Sealed predictions
- TNFRSF8 in dopamine neurons, braak-0.56 (p 0.116) → +0.10 (p 0.807)receipt 7094
Swarm cases
receipt 7094: TNFRSF8 in dopamine neurons, braak
- power
- full sample -0.20 (p 0.418, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.369, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.429, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.10, sign flips 0; without severely affected donors -0.20 (p 0.418, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TNFRSF8 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts